Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Chief Medical Officer | August 14, 2019 | August 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date August 14, 2019 · Filed August 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,932 |
Reported balance
After 2019-08-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-08-14 · Exercise / conversion · Acquired 5,000 · Balance 148,932 F1: Includes (i) the following Restricted Stock Units ("RSUs") that will be settled into common stock upon a "Change In Control," as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 20,000 RSUs granted on March 15, 2018 and (b) 100,000 RSUs granted on May 11, 2017; (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant and the first and second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting: (a) 8,134 RSUs granted on July 22, 2019 and unvested as of the date hereof, (b) 3,080 RSUs granted on March 4, 2019 and unvested as of the date hereof and (c) 4,667 RSUs granted on February 28, 2018 and unvested as of the date hereof; and (iii) 13,051 shares of common stock owned by the reporting person, inclusive of the 5,000 shares of common stock reported on this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2027-05-11 | Direct | 35,000 |
Reported balance
After 2019-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-08-14 · Exercise / conversion · Disposed 5,000 · Balance 35,000 F2: The option, representing a right to purchase a total of 40,000 shares of common stock, became exercisable as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes (i) the following Restricted Stock Units ("RSUs") that will be settled into common stock upon a "Change In Control," as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 20,000 RSUs granted on March 15, 2018 and (b) 100,000 RSUs granted on May 11, 2017; (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant and the first and second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting: (a) 8,134 RSUs granted on July 22, 2019 and unvested as of the date hereof, (b) 3,080 RSUs granted on March 4, 2019 and unvested as of the date hereof and (c) 4,667 RSUs granted on February 28, 2018 and unvested as of the date hereof; and (iii) 13,051 shares of common stock owned by the reporting person, inclusive of the 5,000 shares of common stock reported on this Form 4.
F2: The option, representing a right to purchase a total of 40,000 shares of common stock, became exercisable as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2019 Filed Aug 16, 2019 18:35 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001144204-19-040380 · tv527778_4.xml · derivative · entry 2 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 5,000 shares Expires 2027-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 40,000 shares of common stock, became exercisable as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 18:35 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 5,000 | $4.50 | $22,500.00 |
DisclosureSEC source: 0001144204-19-040380 · tv527778_4.xml · nonDerivative · entry 1 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) the following Restricted Stock Units ("RSUs") that will be settled into common stock upon a "Change In Control," as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 20,000 RSUs granted on March 15, 2018 and (b) 100,000 RSUs granted on May 11, 2017; (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant and the first and second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting: (a) 8,134 RSUs granted on July 22, 2019 and unvested as of the date hereof, (b) 3,080 RSUs granted on March 4, 2019 and unvested as of the date hereof and (c) 4,667 RSUs granted on February 28, 2018 and unvested as of the date hereof; and (iii) 13,051 shares of common stock owned by the reporting person, inclusive of the 5,000 shares of common stock reported on this Form 4. Read SEC document |
| July 22, 2019 Filed Jul 25, 2019 00:17 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 48,700 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001144204-19-035841 · tv525807_4.xml · derivative · entry 2 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,700 Underlying: Common Stock · 48,700 shares Expires 2029-07-22 F3 · derivative.exercise_date: The stock option was granted pursuant to the Plan. The shares underlying the stock option vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date. Read SEC document |
| July 22, 2019 Filed Jul 25, 2019 00:17 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-035841 · tv525807_4.xml · nonDerivative · entry 1 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,612 F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 20,000 RSUs granted on March 15, 2018 and (b) 100,000 RSUs granted on May 11, 2017; (ii) the following RSUs subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting: (a) 12,200 RSUs granted on July 22, 2019 and reported on this Form 4, (b) 4,667 RSUs granted on February 28, 2018 and unvested as of the date hereof and (c) 3,080 RSUs granted on March 4, 2019 and unvested as of the date hereof; and (iii) 5,665 shares of common stock owned by the reporting person. Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 02:09 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-012634 · tv515701_4.xml · nonDerivative · entry 1 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,166 F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) the 20,000 RSUs granted on March 15, 2018 that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation, as defined in the 2014 Long-Term Incentive Plan, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting: (a) 4,667 RSUs granted on February 28, 2018 and (b) 4,620 RSUs granted on March 4, 2019 and reported on this Form 4, and (iii) 4,879 shares of common stock owned by the reporting person. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 14:58 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001144204-18-015762 · tv488961_4.xml · derivative · entry 2 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-03-15 F3 · derivative.exercise_date: Such options were granted pursuant to the Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of the Company. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 14:58 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-015762 · tv488961_4.xml · nonDerivative · entry 1 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) 20,000 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) 14,000 RSUs granted on February 28, 2018, and subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting, and (iii) 2,500 shares of common stock owned by the reporting person. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:27 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012644 · tv487692_form4.xml · nonDerivative · entry 1 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 F1 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes 2,500 shares of common stock owned by the reporting person and 14,000 restricted stock units granted on February 28, 2018 and reported on this Form 4. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 22:18 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 2,500 | $4.04 | $10,099.50 |
DisclosureSEC source: 0001144204-17-032389 · v468859_4.xml · nonDerivative · entry 1 Mortensen Eric R. · CIK 0001708454 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.